Brainsway

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ido Marom, an experienced senior financial leader in global industries, including medical technology, as Chief Financial Officer (CFO). Mr. Marom will succeed Scott Areglado, who will be stepping down from the Company to pursue other opportunities.

BrainsWay Announces Appointment of Ido Marom as CFO

BrainsWay Ltd. (NASDAQ:BWAY ) Q1 2023 Earnings Call May 17, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer Scott Areglado - Senior Vice President and Chief Financial Officer Conference Call Participants Steve Lichtman - Oppenheimer Jeffery Cohen - Ladenburg Thalmann Glenn Shell - Raymond James Carl Byrnes - Northland Capital Markets Boobalan Pachaiyappan - H.C.

BrainsWay Ltd. (BWAY) Q1 2023 Earnings Call Transcript

BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported first quarter 2023 financial results and provided an operational update.

BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights

Application Period Open for Data Collaboration and Equipment Loan Initiatives Application Period Open for Data Collaboration and Equipment Loan Initiatives

BrainsWay Launches Investigator Initiated Study (IIS) Program

Brainsway Ltd. Sponsored ADR (BWAY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.

Brainsway Ltd. Sponsored ADR (BWAY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

BURLINGTON, Mass. and JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2023 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, May 17, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report First Quarter 2023 Financial Results on May 17, 2023

Real-World Evidence Demonstrates the Highest Response and  Remission Rates Observed to Date for Deep

BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious Depression

BrainsWay Ltd. (NASDAQ:BWAY ) Q4 2022 Earnings Conference Call March 15, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer Scott Areglado - Senior Vice President and Chief Financial Officer Conference Call Participants Steve Lichtman - Oppenheimer Jeffrey Cohen - Ladenburg Thalmann Boobalan Pachaiyappan - H.

BrainsWay Ltd. (BWAY) Q4 2022 Earnings Call Transcript

BURLINGTON, Mass. and JERUSALEM, March 15, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported fourth quarter and full-year 2022 financial results and provided an operational update.

BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, Israel, March 01, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2022 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, March 15, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023

Neuronetics Inc

I am bullish on the niche industry that uses magnetic stimulation for brain therapies. BrainsWay and Neuronetics are US-listed stocks in this niche, however they are highly unprofitable with volatile sales growth.

Why I Am Passing On BrainsWay And Neuronetics

BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Hadar Levy, the Company's Senior Vice President (SVP) and Chief Operating Officer (COO), and a member of BrainsWay's senior leadership team since 2014, as Chief Executive Officer (CEO). Mr. Levy has been instrumental as a sales, financial and operational leader for the Company throughout his tenure at BrainsWay, previously serving as the Company's Chief Financial Officer and then General Manager North America, before assuming his role as SVP and COO. Mr. Levy succeeds Christopher R. von Jako, Ph.D., who has decided to step down from the Company to pursue other opportunities.

BrainsWay Announces Appointment of Hadar Levy as CEO

David Zacut, M.D., Relinquishing Chairman Role Held Since Company's Inception, to Now Serve as Board Director David Zacut, M.D., Relinquishing Chairman Role Held Since Company's Inception, to Now Serve as Board Director

BrainsWay Announces Appointment of Ami Boehm as New Chairman

Advanced Micro Devices

Dime Community Bank

AMD, BWAY and DCOM have been added to the Zacks Rank #5 (Strong Sell) List on February 7, 2023.

New Strong Sell Stocks for February 7th

CareMax

Equity Bancshares

BWAY, CMAX and EQBK have been added to the Zacks Rank #5 (Strong Sell) List on February 1, 2023.

New Strong Sell Stocks for February 1st

Bank First Corp

BFC, CMAX and BWAY have been added to the Zacks Rank #5 (Strong Sell) List on January 30, 2023.

New Strong Sell Stocks for January 30th

CNX Resources

Independent Bank

BWAY, INDB and CNX have been added to the Zacks Rank #5 (Strong Sell) List on January 26, 2023.

New Strong Sell Stocks for January 26th

ABM Industries

DXP Enterprises

ABM, BWAY and DXPE have been added to the Zacks Rank #5 (Strong Sell) List on January 24, 2023.

New Strong Sell Stocks for January 24th

ABM, BWAY and DXPE have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022.

New Strong Sell Stocks for January 19th

BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that a major private insurance company in Washington state will extend positive coverage applicable to Deep Transcranial Magnetic Stimulation (Deep TMS™) for the treatment of obsessive-compulsive disorder (OCD) as of February 3, 2023. This policy extension provides coverage of Deep TMS for OCD to approximately 2.2 million members.

BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™

Adient

American Axle & Manufacturing Hlds

BWAY, BWAY and AXL have been added to the Zacks Rank #5 (Strong Sell) List on January 10, 2023.

New Strong Sell Stocks for January 10th

BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported that it has settled litigation filed by Neuronetics, Inc. (“Neuronetics”) in the District of Delaware.

BrainsWay Resolves Neuronetics Litigation

BURLINGTON, Mass. and JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported a recent open market purchase of BrainsWay American Depositary Receipts (ADRs) by Yossi Ben Shalom, an independent Director on the Company's Board.

BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben Shalom

BURLINGTON, Mass. and JERUSALEM, Nov. 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported that David Zacut, M.D., BrainsWay's Chairman of the Board of Directors, and Avner Hagai, an independent Director on BrainsWay's Board, separately purchased BrainsWay ordinary shares in recent open market purchases.

BrainsWay Reports Open Market Stock Purchases by Two Board Members

BrainsWay Ltd. (NASDAQ:BWAY ) Q3 2022 Results Earnings Conference Call November 16, 2022 8:30 AM ET Company Participants Bob Yedid - Investor Relations, LifeSci Advisors Christopher von Jako - President and Chief Executive Officer Scott Areglado - Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer & Co. Inc. Jeffery Cohen - Ladenburg Thalmann Jayson Bedford - Raymond James & Associates, Inc. Boobalan Pachaiyappan - H.C.

News for Brainsway Stock (BWAY)